4.7 Review

Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

期刊

MOLECULAR ONCOLOGY
卷 10, 期 10, 页码 1497-1515

出版社

WILEY
DOI: 10.1016/j.molonc.2016.09.003

关键词

Histone methyltransferase; Breast cancer; Chromatin; Transcription; Inhibitors

类别

资金

  1. Australian National Health and Medical Research Council (NHMRC) [1016701, 1024852, 1086727]
  2. NHMRC IRIISS
  3. Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium
  4. Australian Cancer Research Foundation
  5. National Breast Cancer Foundation Career Development Fellowship
  6. NHMRC Australia Fellowship
  7. National Health and Medical Research Council of Australia [1086727] Funding Source: NHMRC
  8. National Breast Cancer Foundation [ECF-15-002] Funding Source: researchfish

向作者/读者索取更多资源

Histone methyltransferases (HMTs) catalyze the methylation of lysine and arginine residues on histone tails and non-histone targets. These important post-translational modifications are exquisitely regulated and affect chromatin compaction and transcriptional programs leading to diverse biological outcomes. There is accumulating evidence that genetic alterations of several HMTs impinge on oncogenic or tumor-suppressor functions and influence both cancer initiation and progression. HMTs therefore represent an opportunity for therapeutic targeting in those patients with tumors in which HMTs are dysregulated, to reverse the histone marks and transcriptional programs associated with aggressive tumor behavior. In this review, we describe the known histone methyltransferases and their emerging roles in breast cancer tumorigenesis. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据